{"filing":{"accession_number":"0001437749-26-021707","cik":"0001385818","ticker":"AYTU","company_name":"AYTU BIOPHARMA, INC","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"aytu20260624c_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926021707/aytu20260624c_8k.htm"},"events":[{"id":13945,"run_id":12398,"accession_number":"0001437749-26-021707","anchor_item_number":"1.02","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses termination of an exclusive license agreement for Metadate CD® that generated $49,000 in net revenue in Q1 FY2026. While the revenue is modest, the termination of a material definitive agreement (Item 1.02) represents a significant change in the Company's commercial arrangements and product portfolio. This qualifies as a material event affecting the registrant's business operations and investor assessment, though the modest revenue scale and lack of disclosed financial impact (penalties, charges) moderates confidence slightly below the highest level.","company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11235,"accession_number":"0001437749-26-021707","item_number":"1.02","item_title":"Termination of Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of an exclusive license agreement for Metadate CD® that generated $49,000 in net revenue in Q1 FY2026. While the revenue is modest, the termination of a material definitive agreement (Item 1.02) represents a significant change in the Company's commercial arrangements and product portfolio. This qualifies as a material event affecting the registrant's business operations and investor assessment, though the modest revenue scale and lack of disclosed financial impact (penalties, charges) moderates confidence slightly below the highest level.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:33:37.575392+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11235,"accession_number":"0001437749-26-021707","item_number":"1.02","item_title":"Termination of Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of an exclusive license agreement for Metadate CD® that generated $49,000 in net revenue in Q1 FY2026. While the revenue is modest, the termination of a material definitive agreement (Item 1.02) represents a significant change in the Company's commercial arrangements and product portfolio. This qualifies as a material event affecting the registrant's business operations and investor assessment, though the modest revenue scale and lack of disclosed financial impact (penalties, charges) moderates confidence slightly below the highest level.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:33:37.575392+00:00","company_name":"AYTU BIOPHARMA, INC","ticker":"AYTU","filing_date":"2026-06-25"}]}